Adamas Pharmaceuticals (NASDAQ:ADMS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The firm presently has a $40.00 price objective on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 12.20% from the company’s current price.
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
Several other equities research analysts have also recently commented on the company. Piper Jaffray Companies set a $52.00 target price on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 19th. BidaskClub cut Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 14th. Cowen set a $55.00 target price on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, December 13th. Northland Securities began coverage on Adamas Pharmaceuticals in a research note on Wednesday, November 29th. They issued an “outperform” rating on the stock. Finally, Noble Financial upped their price objective on Adamas Pharmaceuticals from $33.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. Adamas Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $44.86.
Adamas Pharmaceuticals (NASDAQ:ADMS) traded up $1.76 during midday trading on Wednesday, reaching $35.65. The company’s stock had a trading volume of 717,900 shares, compared to its average volume of 620,350. The company has a market cap of $802.73, a PE ratio of -10.61 and a beta of 1.13. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.35 and a quick ratio of 8.32. Adamas Pharmaceuticals has a 12-month low of $13.50 and a 12-month high of $38.22.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by ($0.03). The company’s revenue was down 99.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.66) earnings per share. sell-side analysts forecast that Adamas Pharmaceuticals will post -3.84 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC bought a new stake in shares of Adamas Pharmaceuticals during the 2nd quarter worth approximately $606,000. Granite Point Capital Management L.P. increased its holdings in shares of Adamas Pharmaceuticals by 11.9% during the 2nd quarter. Granite Point Capital Management L.P. now owns 263,515 shares of the specialty pharmaceutical company’s stock worth $4,609,000 after acquiring an additional 28,000 shares during the last quarter. Hikari Power Ltd acquired a new position in shares of Adamas Pharmaceuticals during the 3rd quarter worth approximately $635,000. EAM Investors LLC acquired a new position in shares of Adamas Pharmaceuticals during the 3rd quarter worth approximately $1,795,000. Finally, Vanguard Group Inc. increased its holdings in shares of Adamas Pharmaceuticals by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock worth $13,034,000 after acquiring an additional 28,818 shares during the last quarter. Institutional investors own 79.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Adamas Pharmaceuticals (ADMS) Raised to “Buy” at Zacks Investment Research” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/03/adamas-pharmaceuticals-adms-raised-to-buy-at-zacks-investment-research.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.